信隆健康: 监事会关于回购注销部分限制性股票的核查意见

Core Points - The company plans to repurchase and cancel 1,818,050 shares of restricted stock that have been granted but not yet unlocked under the 2023 Restricted Stock Incentive Plan [1][2] - The repurchase is due to certain incentive recipients either resigning or passing away, resulting in unvested shares that need to be canceled [1][2] - The repurchase price is set at 3.49 yuan per share, plus applicable bank interest for the deceased recipient's shares [1][2] Summary by Sections - Repurchase Details - The company will use its own funds to repurchase the restricted shares, which will be submitted for approval at the upcoming shareholders' meeting [2] - The repurchase includes shares from two individuals who resigned and one individual who passed away, totaling 55,000 shares and 20,000 shares respectively [1][2] - Compliance and Approval - The supervisory board confirms that the repurchase complies with relevant laws and regulations, ensuring no adverse effects on the company's financial status or the interests of shareholders, particularly minority shareholders [2] - The matter requires approval from the shareholders' meeting before implementation [2]